| Literature DB >> 34423148 |
Edmund K K Brakohiapa1, Benjamin D Sarkodie1, Benard O Botwe2, Klenam Dzefi-Tettey3, Dorothea A Anim3, Emmanuel K M Edzie4, Philip N Goleku4, Bashiru B Jimah4, Adu Tutu Amankwa5.
Abstract
INTRODUCTION: The novel corona virus popularly referred to as COVID-19 disease and SARS-CoV-2 was first detected in Wuhan, China in December 2019. It was declared a pandemic by the World Health Organization (WHO) on March 11, 2020. In Ghana, the first two cases of COVID-19 infection were recorded on March 13, 2020 with a strain imported from Europe. In December 2020, a new strain from South Africa was detected in Ghana which was associated with higher transmission rates, severity of the disease, and higher number of recorded deaths. Our study aimed to record notable differences and similarities between infections due to the initial, and second strains of COVID-19 infections detected in Ghana during the last 12-months.Entities:
Keywords: COVID-19; Lung diseases; Multidetector computed tomography; SARS-CoV-2
Year: 2021 PMID: 34423148 PMCID: PMC8372493 DOI: 10.1016/j.heliyon.2021.e07818
Source DB: PubMed Journal: Heliyon ISSN: 2405-8440
Figure 1Gender distribution of patients.
Figure 2Age range distribution of patients.
Distribution of symptoms presented by patients.
| Age | Gender | 2020 | 2021 | ||
|---|---|---|---|---|---|
| Asymptomatic | Symptomatic | Asymptomatic | Symptomatic | ||
| <20 | Male | - | - | 1 | - |
| Female | 1 | - | 1 | - | |
| 20–29 | Male | 1 | - | 1 | - |
| Female | 1 | - | 1 | - | |
| 30–39 | Male | 2 | 2 | 3 | 1 |
| Female | 2 | 2 | 2 | 2 | |
| 40–49 | Male | 3 | 4 | 8 | 3 |
| Female | 3 | 2 | 1 | 2 | |
| 50–59 | Male | 3 | 4 | 3 | - |
| Female | 1 | - | 2 | 1 | |
| 60–69 | Male | 5 | 3 | 6 | 4 |
| Female | 4 | 1 | 1 | - | |
| 70–79 | Male | 2 | 1 | 2 | - |
| Female | - | 2 | 3 | 1 | |
| 80–89 | Male | 1 | 0 | 1 | - |
| Female | 0 | 0 | 1 | - | |
| Total | 29 | 21 | 36 | 14 | |
Distribution of lung involvement.
| Age | Gender | 2020 | 2021 | ||||
|---|---|---|---|---|---|---|---|
| None | Unilateral | Bilateral | None | Unilateral | Bilateral | ||
| <20 | Male | - | - | - | 1 | - | - |
| Female | 1 | - | - | 1 | - | - | |
| 20–29 | Male | - | - | - | - | - | 1 |
| Female | 2 | - | - | 1 | - | - | |
| 30–39 | Male | 3 | - | 1 | - | - | 4 |
| Female | 4 | - | - | 2 | - | 2 | |
| 40–49 | Male | - | - | 7 | 3 | - | 8 |
| Female | 4 | - | 1 | 1 | - | 2 | |
| 50–59 | Male | 1 | - | 6 | - | - | 3 |
| Female | - | 1 | - | 1 | - | 2 | |
| 60–69 | Male | 1 | - | 8 | 1 | 2 | 6 |
| Female | 2 | - | 3 | - | - | 1 | |
| 70–79 | Male | 1 | - | 2 | - | - | 2 |
| Female | - | 1 | - | - | - | 4 | |
| 80–89 | Male | - | - | 1 | - | - | 1 |
| Female | - | - | - | - | - | 1 | |
| Total | 19 | 2 | 29 | 11 | 2 | 37 | |
Distribution of Affected zones of the lungs.
| Age | Gender | 2020 | 2021 | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Affected zones | Affected zones (n) | ||||||||||||||||
| None | UZ | MZ | LZ | LUZ | LMZ | MUZ | AZ | None | UZ | MZ | LZ | LUZ | LMZ | MUZ | AZ | ||
| (n) | (n) | ||||||||||||||||
| <20 | Male | - | - | - | - | - | - | - | - | 1 | - | - | - | - | - | - | - |
| Female | 1 | - | - | - | - | - | - | - | 1 | - | - | - | - | - | - | - | |
| 20–29 | Male | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1 | |
| Female | 2 | - | - | - | - | - | - | - | 1 | - | - | - | - | - | - | - | |
| 30–39 | Male | 3 | 1 | - | - | - | - | - | - | - | - | - | - | - | - | - | 4 |
| Female | 4 | - | - | - | - | - | - | - | 2 | - | - | - | 1 | 1 | - | - | |
| 40–49 | Male | - | - | - | 2 | - | - | 1 | 4 | 3 | - | - | - | - | - | - | 8 |
| Female | 4 | - | - | - | - | - | - | 1 | - | - | - | 1 | - | - | - | 2 | |
| 50–59 | Male | - | - | - | 2 | 2 | 1 | 1 | 1 | - | - | - | - | 2 | - | - | 1 |
| Female | - | - | - | 1 | - | - | - | - | 1 | - | - | - | 1 | - | - | 1 | |
| 60–69 | Male | 1 | - | - | 3 | - | - | - | 5 | 1 | 1 | - | 1 | - | - | - | 6 |
| Female | 2 | - | - | - | 2 | - | - | 1 | - | - | - | - | - | - | - | 1 | |
| 70–79 | Male | 1 | - | - | - | - | - | - | 2 | - | - | - | - | - | 1 | - | 1 |
| Female | - | - | - | - | - | - | - | 1 | - | - | - | - | - | - | - | 4 | |
| 80–89 | Male | - | - | - | 1 | - | - | - | - | - | - | - | - | - | - | 1 | |
| Female | - | - | - | - | - | - | - | - | - | - | - | - | - | 1 | - | - | |
| Total | 18 | 1 | 0 | 8 | 5 | 1 | 2 | 15 | 10 | 1 | 0 | 2 | 4 | 3 | 0 | 30 | |
Distribution key: UZ = upper zone; MZ = mid zone; LZ = lower zone; LUZ = low + upper zone; LMZ = low + mid zone; MUZ = mid + upper zone; AZ = all zones.
Distribution of comorbidities presented by patients.
| Age | Gender | 2020 | 2021 | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Comorbidity (n) | Comorbidity (n) | ||||||||||||
| None | dm | htn | asthma | DVT/PE | Ca | None | dm | htn | asthma | DVT/PE | Ca | ||
| <20 | Male | - | - | - | - | - | - | 1 | - | - | - | - | - |
| Female | 1 | - | - | - | - | - | 1 | - | - | - | - | - | |
| 20–29 | Male | - | - | - | - | - | - | 1 | - | - | - | - | - |
| Female | 2 | - | - | - | - | - | 1 | - | - | - | - | - | |
| 30–39 | Male | 3 | - | - | - | - | - | 3 | - | 1 | - | - | - |
| Female | 4 | - | - | - | - | - | 2 | - | 1 | - | - | 2 | |
| 40–49 | Male | 7 | - | - | - | - | - | 10 | 1 | 1 | - | - | - |
| Female | 5 | - | - | - | - | - | 1 | - | - | - | 1 | - | |
| 50–59 | Male | 5 | 1 | 1 | - | - | 1 | 3 | - | - | - | - | - |
| Female | 1 | - | - | - | - | - | 3 | - | - | - | - | - | |
| 60–69 | Male | 7 | 2 | 1 | 1 | - | - | 8 | 1 | 1 | - | - | - |
| Female | 5 | - | - | - | - | - | 1 | - | - | - | - | - | |
| 70–79 | Male | 3 | - | - | - | - | - | 2 | - | - | - | - | - |
| Female | 1 | - | - | - | - | - | 2 | - | 0 | - | 1 | - | |
| 80–89 | Male | 1 | - | - | - | 1 | - | 1 | - | - | - | - | - |
| Female | 0 | - | - | - | - | - | 1 | - | - | - | - | - | |
| Total | 45 | 3 | 2 | 1 | 1 | 1 | 43 | 2 | 4 | 0 | 2 | 2 | |
Key: dm = diabetes; htn = hypertension; DVT/PE = deep vein thrombosis/pulmonary embolism; Ca= Cancer.
Frequency of high resolution computed tomography (HRCT) findings suggestive of COVID-19 infection.
| Age | Gender | 2020 | 2021 | ||
|---|---|---|---|---|---|
| COVID-19 +ve | COVID-19 −ve | COVID-19 +ve | COVID-19 −ve | ||
| <20 | Male | - | - | - | 1 |
| Female | - | 1 | - | 1 | |
| 20–29 | Male | - | - | 1 | - |
| Female | - | 2 | - | 1 | |
| 30–39 | Male | - | 4 | 4 | - |
| Female | - | 4 | 2 | 2 | |
| 40–49 | Male | 6 | - | 8 | 3 |
| Female | 2 | 4 | 2 | 1 | |
| 50–59 | Male | 7 | - | 3 | - |
| Female | 1 | - | 2 | 1 | |
| 60–69 | Male | 8 | 1 | 8 | 1 |
| Female | 3 | 2 | 1 | - | |
| 70–79 | Male | 2 | 1 | 1 | - |
| Female | 1 | - | 5 | - | |
| 80–89 | Male | 1 | - | 1 | - |
| Female | - | - | 1 | - | |
| Total | 31 | 19 | 39 | 11 | |
Key: COVID-19 +ve = CT features suggestive of COVID-19 infection; COVID-19 −ve = CT features suggestive of no COVID-19 infection on HRCT images. Note: All patients were RT-PCR positive for COVID-19.
Distribution of severity of disease.
| Age | Gender | 2020 | 2021 | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Severity (n) | Severity (n) | ||||||||
| Nil of note | Mild | Moderate | Severe | Nil of note | Mild | Moderate | Severe | ||
| <20 | Male | - | - | - | - | 1 | - | - | - |
| Female | 1 | - | - | - | 1 | - | - | - | |
| 20–29 | Male | - | - | - | - | - | 1 | - | - |
| Female | 2 | - | - | - | 1 | - | - | - | |
| 30–39 | Male | 3 | 1 | - | - | - | 2 | 2 | - |
| Female | 4 | - | - | - | 2 | 1 | 1 | - | |
| 40–49 | Male | - | 3 | 4 | - | 3 | 4 | 4 | - |
| Female | 4 | - | - | 1 | - | 2 | 1 | - | |
| 50–59 | Male | - | 5 | 2 | - | - | 2 | 1 | - |
| Female | - | 1 | - | - | 1 | - | 2 | - | |
| 60–69 | Male | 1 | 6 | 2 | - | 1 | 3 | 3 | 2 |
| Female | 3 | - | 2 | - | - | - | 1 | - | |
| 70–79 | Male | 1 | - | 2 | - | - | 2 | - | - |
| Female | - | 1 | - | - | - | - | 2 | 2 | |
| 80–89 | Male | - | 1 | - | - | - | - | - | 1 |
| Female | - | - | - | - | - | 1 | - | - | |
| Total | 19 | 18 | 12 | 1 | 10 | 18 | 17 | 5 | |
Distribution of CT findings.
| Age | Gender | 2020 | 2021 | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CT findings | CT findings | ||||||||||||||
| None | Cons. | Fibr. | GG den. | Cavity | Pleural eff. | C | None | Cons. | Fibr. | GG den. | Cavity | Pleural eff. | DC | ||
| (n) | (n) | ||||||||||||||
| <20 | Male | - | - | - | - | - | - | - | 1 | - | - | - | - | - | - |
| Female | 1 | - | - | - | - | - | - | 1 | - | - | - | - | - | - | |
| 20–29 | Male | - | - | - | - | - | - | - | 1 | - | - | - | - | - | |
| Female | 2 | - | - | - | - | - | - | 1 | - | - | - | - | - | - | |
| 30–39 | Male | 3 | 1 | - | - | - | - | - | - | 4 | - | - | - | - | - |
| Female | 4 | - | - | - | - | - | - | 2 | 1 | - | 1 | - | - | - | |
| 40–49 | Male | - | 5 | - | 2 | - | - | - | 3 | 7 | - | 1 | - | - | - |
| Female | 4 | 1 | - | - | - | - | - | - | 1 | 1 | 1 | - | - | 1 | |
| 50–59 | Male | - | 7 | - | 1 | - | - | - | - | 3 | 1 | - | - | - | - |
| Female | - | 1 | - | - | - | 1 | 2 | - | - | - | - | - | |||
| 60–69 | Male | 1 | 5 | 3 | 4 | 1 | 1 | - | 1 | 6 | 1 | - | - | - | - |
| Female | 2 | 2 | 1 | - | - | - | - | - | 1 | - | - | - | - | - | |
| 70–79 | Male | 1 | 2 | 1 | - | - | - | - | - | - | - | 2 | - | - | 1 |
| Female | - | 1 | - | - | - | - | - | - | 3 | 1 | 1 | - | 1 | - | |
| 80–89 | Male | - | 1 | - | 1 | - | - | - | - | 1 | - | - | - | - | |
| Female | - | - | - | - | - | - | - | - | 1 | - | 1 | - | - | - | |
| Total | 18 | 26 | 5 | 8 | 1 | 1 | 0 | 9 | 31 | 4 | 7 | 0 | 1 | 2 | |
Key: Cons = consolidation; Fibr. = fibrosis; GG den. = ground glass densities; Pleural eff. = pleural effusion; C = Cardiomegaly.
History-frequency for both 2020 and 2021 cases.
| History | 2020 | 2021 | Total of 2020 and 2021 | ||||
|---|---|---|---|---|---|---|---|
| Frequency (n) | Frequency (n) | ||||||
| Male | Female | Total | Male | Female | Total | ||
| None | - | 2 | 2 | - | - | - | 2 |
| Sore throat | - | 1 | 1 | - | - | - | 1 |
| Cough | 2 | 0 | 2 | 2 | 1 | 3 | 5 |
| SOB/dyspnea | 2 | 1 | 3 | 1 | 1 | 2 | 5 |
| Headache | - | - | - | - | - | - | 0 |
| GI symptoms | - | - | - | - | - | - | 0 |
| Chest discomfort/pain | 3 | 1 | 4 | - | - | - | 4 |
| Myalgia/arthralgia | 1 | - | 1 | - | - | - | 1 |
| COVID-19 +ve | 6 | 8 | 14 | 22 | 12 | 34 | 48 |
| ? COVID-19 | 8 | 6 | 14 | 2 | 0 | 2 | 16 |
| Fever | 2 | - | 2 | - | - | - | 2 |
| Cancer | 1 | - | 1 | - | - | - | 1 |
| General malaise | 1 | - | 1 | - | - | - | 1 |
| Cough, SOB/dyspnoea and Fever | 1 | - | 1 | - | - | - | 1 |
| Cough and SOB/dyspnoea | - | - | - | 1 | 1 | 2 | 2 |
| Cough, SOB/dyspnoea, Fever and COVID-19 +ve | - | - | - | 1 | - | 1 | 1 |
| Cough, myalgia/arthralgia and COVID +ve | - | - | - | 1 | - | 1 | 1 |
| COVID +ve and SOB/dyspnoea | - | - | - | 1 | - | 1 | 1 |
| Cough and Fever | 3 | 1 | 4 | - | - | - | 4 |
| COVID +ve and general malaise | - | - | 1 | - | 1 | 1 | |
| COVID-19 +ve and cough | - | - | - | - | - | - | - |
| COVID-19 +ve, cough and SOB/dyspnoea | - | - | - | - | 1 | 1 | 1 |
| COVID-19 +ve, cough, fever and general malaise | - | - | - | - | 1 | 1 | 1 |
| COVID-19 +ve, cough, SOB/dyspnoea and myalgia/arthralgia | - | - | - | - | 1 | 1 | 1 |
| Total | 30 | 20 | 50 | 32 | 18 | 50 | 100 |
Key: COVID-19 +ve = COVID-19 infection which has been confirmed by a positive PCR test prior to HRCT scanning ?COVID-19 = suspected COVID-19 infection confirmed by a positive PCR test, from throat and nasal swab samples taken immediately after HRCT scanning.
Clinical history - frequency of patients with respect to age categories for 2020 & 2021 cases.
| History | Female | Male | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Year group | Year group | |||||||||||||||
| <20 | 20–29 | 30–39 | 40–49 | 50–59 | 60–69 | 70–79 | 80–89 | <20 | 20–29 | 30–39 | 40–49 | 50–59 | 60–69 | 70–79 | 80–89 | |
| (n) | (n) | |||||||||||||||
| None | 2 | - | - | 1 | - | - | - | - | - | - | - | - | - | - | - | - |
| Sore throat | - | - | - | 1 | - | - | - | - | - | - | - | - | - | - | - | - |
| Cough | - | - | - | - | - | - | - | - | - | - | - | 1 | - | 3 | - | - |
| SOB/dyspnea | - | - | 2 | - | - | - | - | - | - | - | - | - | - | 2 | - | 1 |
| Headache | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| GI symptoms | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Chest discomfort/pain | - | - | 1 | - | - | - | - | - | - | - | - | 2 | 1 | - | - | - |
| Myalgia/arthralgia | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1 | - |
| COVID +ve | - | 3 | 3 | 2 | 3 | 4 | 4 | - | - | 1 | 5 | 8 | 4 | 7 | 2 | - |
| ?COVID | - | - | 1 | 1 | - | 3 | 1 | 1 | - | - | 1 | 3 | 2 | 3 | 1 | 1 |
| Fever | - | - | - | - | - | - | - | - | - | - | - | 1 | 1 | - | - | |
| Cancer | - | - | - | - | - | - | - | - | - | - | - | - | 1 | - | - | - |
| General malaise | - | - | - | - | - | - | - | - | - | - | - | - | 1 | - | - | |
| Cough and fever | - | - | - | 1 | - | - | - | - | - | - | 1 | - | 1 | - | 1 | - |
| Cough, SOB/dyspnoea | - | - | - | 1 | - | - | - | - | - | - | - | - | - | - | - | - |
| General malaise, fever, COVID-19 +ve and cough | - | - | - | 1 | - | - | - | - | - | - | - | - | - | - | - | - |
| Cough, SOB/dyspnoea, myalgia/arthralgia and COVID-19 +ve | - | - | 1 | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Cough and SOB/dyspnea | - | - | - | - | 1 | - | - | - | - | - | - | 1 | - | - | - | - |
| SOB/dyspnoea and COVID +ve | - | - | - | - | - | - | - | - | - | - | 1 | - | - | - | - | - |
| COVID +ve and general malaise | - | - | - | - | - | - | - | - | - | - | - | 1 | - | - | - | - |
| Cough, myalgia/arthralgia and COVID +ve | - | - | - | - | - | - | - | - | - | - | - | 1 | - | - | - | - |
| Cough, SOB/dyspnoea and fever | - | - | - | - | - | - | - | - | - | - | - | - | 1 | - | - | - |
| Cough, SOB/dyspnoea, COVID-19 +ve and fever | - | - | - | - | - | - | - | - | - | - | - | - | - | 1 | ||
| Total | 2 | 3 | 8 | 8 | 4 | 7 | 5 | 1 | 0 | 1 | 8 | 18 | 10 | 18 | 5 | 2 |
Key: COVID-19 +ve = COVID-19 infection which has been confirmed by a positive PCR test prior to HRCT scanning ?COVID-19 = suspected COVID-19 infection confirmed by a positive PCR test, from throat and nasal swab samples taken immediately after HRCT scanning.